Lipinski's Rule of Five

From Self-sufficiency
Revision as of 19:54, 25 June 2010 by RibotBOT (Talk) (robot Modifying: es:Regla de cinco de Lipinsky)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Lipinski's Rule of Five is a rule of thumb to evaluate druglikeness, or determine if a chemical compound with a certain pharmacological or biological activity has properties that would make it a likely orally active drug in humans. The rule was formulated by Christopher A. Lipinski in 1997, based on the observation that most medication drugs are relatively small and lipophilic molecules.[1]

The rule describes molecular properties important for a drug's pharmacokinetics in the human body, including their absorption, distribution, metabolism, and excretion ("ADME"). However, the rule does not predict if a compound is pharmacologically active.

The rule is important for drug development where a pharmacologically active lead structure is optimized step-wise for increased activity and selectivity, as well as drug-like properties as described by Lipinski's rule. The modification of the molecular structure often leads to drugs with higher molecular weight, more rings, more rotatable bonds, and a higher lipophilicity.[2]

Lipinski's rule says that, in general, an orally active drug has no more than one violation of the following criteria:

Note that all numbers are multiples of five, which is the origin of the rule's name.

Improvements

To evaluate druglikeness better, the rules have spawned many extensions, for example one from a 1999 paper by Ghose et al.:[4]

  • Partition coefficient log P in -0.4 to +5.6 range
  • Molar refractivity from 40 to 130
  • Molecular weight from 160 to 500
  • Number of atoms from 20 to 70 (includes H-bond donors [e.g.;OHs and NHs] and H-bond acceptors [e.g.; Ns and Os])

Over the past decade Lipinski's profiling tool for druglikeness has led to further investigations by scientists to extend profiling tools to lead-like properties of compounds in the hope that a better starting point in early discovery can save time and cost. Some compound searching sites, such as the extensive searching tools on the ASDI website, now allow using Rule-of-5 and other properties to rapidly identify compounds that may be more desireable for high throughput screening and for parallel synthesis efforts[5]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

de:Rule of Five es:Regla de cinco de Lipinsky it:Regola di Lipinski ja:リピンスキーの法則 sl:Pravilo Lipinskega sv:Lipinskis fem regler

zh:里宾斯基五规则
  1. C.A. Lipinski; F. Lombardo; B.W. Dominy and P.J. Feeney (1997). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Adv Drug Del Rev. 23: 3–25. doi:10.1016/S0169-409X(00)00129-0. 
  2. T. I. Oprea, A. M. Davis, S. J. Teague, P. D. Leeson (2001). "Is There a Difference between Leads and Drugs? A Historical Perspective". J. Chem. Inf. Comput. Sci. 41: 1308–1315. doi:10.1021/ci010366a. 
  3. Leo A, Hansch C, and Elkins D (1971). "Partition coefficients and their uses". Chem Rev. 71 (6): 525–616. doi:10.1021/cr60274a001. 
  4. Arup K. Ghose, Vellarkad N. Viswanadhan, and John J. Wendoloski (1999). "A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery". J. Combin. Chem. 1: 55–68. doi:10.1021/cc9800071. 
  5. Michael Wagaman, Greg Silber, et al., ASDI, (2008), see http://web.asdi.net/index.php/online-ordering-system